Friday - January 24, 2025
Congressional Research Service Issues Insight White Paper on Xylazine - Considerations for Federal Control
February 05, 2023
WASHINGTON, Feb. 5 -- The Congressional Research Service issued the following Insight white paper on Xylazine - considerations for federal Control (No. IN12086) on Feb. 2, 2023, by Lisa N. Sacco, illicit drugs and crime policy analyst, and Hassan Z. Sheikh, health policy analyst:

* * *

Xylazine: Considerations for Federal Control

Xylazine is a sedative drug used in veterinary medicine. It is not approved or intended for human consumption. Some drug users in . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products